Endocrine Abstracts

Purpose: To examine two cases of teenagers after transnasal removal of pituitary volume of education followed by recombinant growth hormone therapy Dzhintropinom (Eurofarm).

Materials and methods: During the period of 2014 in the department of paediatric endocrinology and neuroendocrinology RSNPM Endocrinology Center MoH (Tashkent), we examined two male patients, including the patient F., 2.5 g of a craniopharyngioma, and the second patient For 15 years with inactive pituitary adenoma. Patients underwent the following range of studies, including clinical, biochemical blood tests and urine tests, radioimmunoassays hormonal methods of blood tests (prolactin, IGF1, GH, TSH, ACTH, LH, FSH, free testosterone, cortisol, thyroxine), ECG, ultrasound genitals and others. All patients underwent MRI of the pituitary gland. Both patients in 2013 was carried out surgery – transnasal pituitary prostatectomy. In both postoperative patients developed panhypopituitarism: diabetes insipidus, GH deficiency (0.03 nmol/ml at a rate of greater than 2 nmol/l), IGF1 (<35 ng/ml), and hypogonadotropic hypogonadism and short stature patient K. 15 l. In this regard, both patients were assigned to hormone replacement therapy, which included desmopressin, levothyroxine, and genetically engineered growth hormone Dzhintropin (Eurofarm). The latter was assigned based 0.033 ug/kg per day, daily, subcutaneously, in the evening, in the forearm, within 6–8 months.

Results: Based on the investigations, it was found that both patients showed a positive trend during therapy Dzhintropinom, namely significantly increased basal and stimulated (with sample klofellinom) levels of growth hormone. Furthermore, there was a noticeable improvement in the dynamics of growth of the body, namely an average of 6 months to 6 cm.

Conclusions:: patients (children and adults).